目的 观察复方杜仲丸联合硝苯地平缓释片（II）治疗妊娠高血压综合征的临床疗效。方法 纳入2024年2月—2025年2月在青岛市妇女儿童医院产科确诊并住院治疗的妊娠期高血压综合征患者93例作为研究对象，患者采用计算机生成的随机数字序列分为对照组（46例）和治疗组（47例）。对照组口服硝苯地平缓释片（II），1片/次，1次/d。治疗组在对照组基础上口服复方杜仲丸，8丸/次，3次/d。两组均治疗7 d。对比两组患者的临床疗效、血压、子宫动脉血流动力学参数、血清学指标、凝血功能和不良妊娠结局事件发生情况。结果 治疗组的总有效率为91.49%，高于对照组的总有效率69.57%（P＜0.05）。治疗后，两组收缩压（SBP）、舒张压（DBP）下降（P＜0.05），治疗组的SBP、DBP低于对照组（P＜0.05）。治疗后，两组最大血流速度比值（S/D）、搏动指数（PI）和阻力指数（RI）下降（P＜0.05），治疗组的S/D、PI、RI低于对照组（P＜0.05）。治疗后，两组纤维蛋白原（FIB）下降，凝血酶时间（TT）、部分凝血活酶时间（APTT）、凝血酶原时间（PT）升高（P＜0.05）；治疗后，治疗组的FIB低于对照组，TT、APTT、PT高于对照组（P＜0.05）。治疗后，两组的缺氧诱导因子-α（HIF-α）、同型半胱氨酸（Hcy）下降，血管内皮生长因子（VEGF）、胎盘生长因子（PLGF）升高（P＜0.05）；治疗后，治疗组的HIF-α、Hcy低于对照组，VEGF、PLGF高于对照组（P＜0.05）。治疗组患者的不良妊娠结局事件发生率低于对照组（P＜0.05）。结论 复方杜仲丸联合硝苯地平缓释片（II）治疗妊娠高血压综合征可显著提高临床疗效，改善凝血功能、子宫动脉血流动力学和血清学指标，降低不良妊娠结局事件发生率。

Objective To observe the clinical efficacy of Compound Duzhong Pills combine with Nifedipine Sustained Release Tablets (Ⅱ) in treatment of pregnancy induced hypertension syndrome. Methods A total of 93 pregnant women diagnosed with pregnancy induced hypertension syndrome and hospitalized at Department of Obstetrics Qingdao Women and Children’s Hospital from February 2024 to February 2025 were included as study subjects. The patients were divided into control group (46 cases) and treatment group (47 cases) using computer-generated random number sequences. The control group received oral Nifedipine Sustained Release Tablets (Ⅱ), 1 tablets/time, once daily. The treatment group additionally took Compound Duzhong Pills on the base of the control group, 8 pills/time, three times daily. Two groups were treated for 7 d. Clinical efficacy, blood pressure, uterine artery hemodynamic parameters, serum indicators, coagulation function, and adverse pregnancy outcomes were compared between two groups. Results The overall effective rate of the treatment group was 91.49%, which was higher than 69.57% of the control group (P < 0.05). After treatment, systolic blood pressure (SBP) and diastolic blood pressure (DBP) in two groups decreased (P < 0.05), and SBP and DBP in the treatment group was lower than that of the control group (P < 0.05). After treatment, maximum blood flow velocity ratio (S/D), pulsatility index (PI), and resistance index (RI) in two groups reduced (P < 0.05), and S/D, PI, and RI in the treatment group was lower than that of the control group (P < 0.05). After treatment, fibrinogen (FIB) levels in two groups decreased, while thrombin time (TT), activated partial thromboplastin time (APTT), and prothrombin time (PT) increased (P < 0.05). After treatment, FIB level in the treatment group was lower than that in the control group, while TT, APTT, and PT were higher than that in the control group (P < 0.05). After treatment, hypoxia-inducible factor-α (HIF-α) and homocysteine (Hcy) in two groups decreased, while vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) in two groups increased (P < 0.05). After treatment, HIF-α and Hcy levels in the treatment group were lower than those of control group, but VEGF and PLGF levels were higher compared to the control group (P < 0.05). The incidence of adverse pregnancy outcomes in the treatment group was lower than that in the control group (P < 0.05). Conclusion The combination of Compound Duzhong Pills and Nifedipine Sustained Release Tablets (Ⅱ) can significantly improve clinical efficacy in treatment of pregnancy induced hypertension syndrome, improve coagulation function, uterine artery hemodynamics, and serum indicators, and reduce the incidence of adverse pregnancy outcome.

R984

山东省自然科学基金创新发展联合基金项目（ZR2022LZY269）